Belarus. Pharmaceutical market: trends 2010
Belarusian pharmaceutical market grew by 10%
Belarusian pharmaceutical market maintained the momentum of previous years, hehas not lost in comparison with Russia, Ukraine, Kazakhstan and in the crisis year of 2009. In 2010, he once again grew.
According to the analytical agency Intellix, the amount of the pharmaceutical market inBelarus last year amounted to 676.4 million dollars. It is almost 10% more than in 2009(615.4 million dollars).
The main reason for growth - Belarusians have to spend more on drugs. Thus, according Intellix, the average annual per capita consumption in wholesale prices in dollars rose from 64.8 to 71.35 U.S. dollars. For comparison: in 2007 the figure was46.6 dollars.
Another trend of last year - Belarusians have to buy more expensive drugs. In the retailmarket, which accounts for about 75% of total sales of drugs, they have increased their spending on drugs in the three most expensive segments. Spending on cheap drugs, by contrast, markedly decreased.
Thus, the share of purchased medicines worth more than $50 increased from 3.73% in 2009 to 4.71% in 2010, valued at 20-50 dollars - from 5.69% to 6.32%, worth U.S. $10-20 - from 11.75% to 12.95%. But the share of drug costs less than a dollar fell from12.62% to 11.43%. An even more dramatic drop was observed in the mass segment - drugs cost between 1 and 5 dollars. They reduced the amount of spending in the total amount of 44.47% to 41.06%.
Interestingly, in the hospital segment, on the contrary, a decrease in spending the most expensive segments was observed.
Continued to decline (in value terms) in 2010, the share of imported drugs. If in 2008 it was 81.9% of total sales in 2010 - is76.57%.
Nevertheless, the three leaders of the two segments of the Belarusian pharmaceutical market (retail and hospital) in sales in 2010 included only the Belarusian manufacturers.
The rating was headed by Belmedpreparaty that sold (in wholesale prices) drugs to39.84 million dollars (an increase compared to 2009 - at 28.09%). Largest share of the Belarusian pharmaceutical market in the production of wholesale sales was 5.89%.The second position - made Farmlend (30.41 million dollars, an increase of 50.19%), the third - in the Borisov Pharmaceuticals Plant (27.94 million dollars, an increase of7.35%).
In physical terms, the leadership of the Belarusians and absolutely both, in total, and among individual producers. In 2010 58.49% - they were selling Belarusian drugs, 41.51% -imported.
In this BZMP became the undisputed champion of the number of packages sold -78.43 million units. For comparison, going after Belmedpreparaty sold 37.29 million packages.
The rest of the top 10 largest manufacturers in the pharmaceutical market of Belarusmade up exclusively of foreign companies. The greatest dynamics demonstrated Nycomed, whose sales rose by 20.35% to $ 23.43 million of dollars. Nycomed quite a bit was not enough to oust from the fourth place, Sanofi-aventis, which sold its products last year for about 25.75 million dollars (an increase - 8.29%).
Positive were Gedeon Richter (total sales - 18.67 million dollars) and GSK (18.5million). On the contrary, negative dynamics showed, Bayer Healthcare (21.58 milliondollars), Roche (18.14 million) and Berlin-Chemie (17.41 million dollars).
Nevertheless, Bayer Healthcare won first place in sales in the retail segment of the Belarusian market, ahead of finishers, respectively, the 2nd and 3rd place Borisov Pharmaceuticals Plant and the Belmedpreparaty. Belarusian Farmlend in this segment was the 6th and 10th place went to another representative of the domestic pharmaceutical industry - Logoisk Lekfarm.
In the hospital segment of the top three sales were Belmedpreparaty, Farmlend and Roche. Among the top 10 were Belarusian Nesvizh Pharmaceuticals Plant (4th place) and BZMP (5).
Leading-brand in the retail market in 2010 was "Lisinopril" (Farmlend), which accounted for 1.15% of total wholesale sales in dollars. Among top three were "Actovegin" (Nycomed) and "Essentiale" (Sanofi-aventis), whose share were 0.81% and 0.67% respectively.
At the hospital market in 2010, the absolute leader in terms of wholesale dollarbecame the Flyuvaksin Chinese company Sheng Chang Changchun Sainz Life - 3,77%. The second and third places went respectively to Koat-Dvi from Talekris Bioterapyutiks Inc. 's (2.44%) and Kurosurf (Nycomed) (2.05%).
Belarusian pharmaceutical market maintained the momentum of previous years, hehas not lost in comparison with Russia, Ukraine, Kazakhstan and in the crisis year of 2009. In 2010, he once again grew.
According to the analytical agency Intellix, the amount of the pharmaceutical market inBelarus last year amounted to 676.4 million dollars. It is almost 10% more than in 2009(615.4 million dollars).
The main reason for growth - Belarusians have to spend more on drugs. Thus, according Intellix, the average annual per capita consumption in wholesale prices in dollars rose from 64.8 to 71.35 U.S. dollars. For comparison: in 2007 the figure was46.6 dollars.
Another trend of last year - Belarusians have to buy more expensive drugs. In the retailmarket, which accounts for about 75% of total sales of drugs, they have increased their spending on drugs in the three most expensive segments. Spending on cheap drugs, by contrast, markedly decreased.
Thus, the share of purchased medicines worth more than $50 increased from 3.73% in 2009 to 4.71% in 2010, valued at 20-50 dollars - from 5.69% to 6.32%, worth U.S. $10-20 - from 11.75% to 12.95%. But the share of drug costs less than a dollar fell from12.62% to 11.43%. An even more dramatic drop was observed in the mass segment - drugs cost between 1 and 5 dollars. They reduced the amount of spending in the total amount of 44.47% to 41.06%.
Interestingly, in the hospital segment, on the contrary, a decrease in spending the most expensive segments was observed.
Continued to decline (in value terms) in 2010, the share of imported drugs. If in 2008 it was 81.9% of total sales in 2010 - is76.57%.
Nevertheless, the three leaders of the two segments of the Belarusian pharmaceutical market (retail and hospital) in sales in 2010 included only the Belarusian manufacturers.
The rating was headed by Belmedpreparaty that sold (in wholesale prices) drugs to39.84 million dollars (an increase compared to 2009 - at 28.09%). Largest share of the Belarusian pharmaceutical market in the production of wholesale sales was 5.89%.The second position - made Farmlend (30.41 million dollars, an increase of 50.19%), the third - in the Borisov Pharmaceuticals Plant (27.94 million dollars, an increase of7.35%).
In physical terms, the leadership of the Belarusians and absolutely both, in total, and among individual producers. In 2010 58.49% - they were selling Belarusian drugs, 41.51% -imported.
In this BZMP became the undisputed champion of the number of packages sold -78.43 million units. For comparison, going after Belmedpreparaty sold 37.29 million packages.
The rest of the top 10 largest manufacturers in the pharmaceutical market of Belarusmade up exclusively of foreign companies. The greatest dynamics demonstrated Nycomed, whose sales rose by 20.35% to $ 23.43 million of dollars. Nycomed quite a bit was not enough to oust from the fourth place, Sanofi-aventis, which sold its products last year for about 25.75 million dollars (an increase - 8.29%).
Positive were Gedeon Richter (total sales - 18.67 million dollars) and GSK (18.5million). On the contrary, negative dynamics showed, Bayer Healthcare (21.58 milliondollars), Roche (18.14 million) and Berlin-Chemie (17.41 million dollars).
Nevertheless, Bayer Healthcare won first place in sales in the retail segment of the Belarusian market, ahead of finishers, respectively, the 2nd and 3rd place Borisov Pharmaceuticals Plant and the Belmedpreparaty. Belarusian Farmlend in this segment was the 6th and 10th place went to another representative of the domestic pharmaceutical industry - Logoisk Lekfarm.
In the hospital segment of the top three sales were Belmedpreparaty, Farmlend and Roche. Among the top 10 were Belarusian Nesvizh Pharmaceuticals Plant (4th place) and BZMP (5).
Leading-brand in the retail market in 2010 was "Lisinopril" (Farmlend), which accounted for 1.15% of total wholesale sales in dollars. Among top three were "Actovegin" (Nycomed) and "Essentiale" (Sanofi-aventis), whose share were 0.81% and 0.67% respectively.
At the hospital market in 2010, the absolute leader in terms of wholesale dollarbecame the Flyuvaksin Chinese company Sheng Chang Changchun Sainz Life - 3,77%. The second and third places went respectively to Koat-Dvi from Talekris Bioterapyutiks Inc. 's (2.44%) and Kurosurf (Nycomed) (2.05%).
Leave a Comment